World Stem Cell Summit
  • About WSCS
    • About Us
    • Past Speakers
    • Annual Regenerative Medicine Essentials Course
    • 2023 Public Day
    • Symposium Intersection of RegMed & Healthspan
    • Effective Patient Advocacy
    • Regenerative Medicine & the Commercial Space Economy
    • Hot Topics in 2023 at World Stem Cell Summit
  • Partners/Sponsors
    • Partners/Sponsors
    • Sponsorship Opportunities
  • Upcoming Events
  • News & Media
    • News and Opinions
    • WSCS 2023 Photos
    • WSCS Video
  • Contact Us
Select Page
New Bio-Implant for Spinal Cord Repair

New Bio-Implant for Spinal Cord Repair

by admin | Mar 6, 2026 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

By Neuroscience News.com – Spinal cord injuries have long been considered permanent because neurons in the central nervous system lack the natural ability to regrow. However, researchershave developed a novel, 3D-printed implant that could change that. The study...
Seattle jury awards M in lawsuit against stem cell center

Seattle jury awards $24M in lawsuit against stem cell center

by admin | Mar 5, 2026 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

By Elise Takahama – Seattle Times – A King County jury has awarded $24 million to the family of a man who died a day after treatment at a Seattle stem cell center. Mike Trujillo was 62, a longtime electrician who ran an electrical company in Colorado....
Phase I/II study finds intravitreal CD34+ stem cells safe and feasible in CRVO

Phase I/II study finds intravitreal CD34+ stem cells safe and feasible in CRVO

by admin | Mar 5, 2026 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

by Lynda Charters – Opthamology – A newly published study found that intravitreal injection of autologous CD34+ stem cells is well tolerated and feasible for treating loss of vision resulting from central retinal vein occlusion (CRVO), according to a press...
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate

After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate

by admin | Mar 4, 2026 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

By Will Maddox – Fierce Biotech – After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate. The agreement, announced in Beam’s...
More Sensitive Cell Therapy May Be a HIT Against Solid Cancers

More Sensitive Cell Therapy May Be a HIT Against Solid Cancers

by admin | Mar 3, 2026 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

By Columbia University Irving Medical Center – CAR-T cell therapy has revolutionized the treatment of many blood cancers, but has shown little success against solid tumors, which account for over 85% of all cancers. Columbia researchers have now found that a new...
New iron nanomaterial wipes out cancer cells without harming healthy tissue

New iron nanomaterial wipes out cancer cells without harming healthy tissue

by admin | Mar 2, 2026 | Bernie Siegel’s WORLD STEM CELL SUMMIT BLOG, News and Opinions

By Oregon State University – Science Daily – Scientists at Oregon State University have engineered a powerful new nanomaterial that zeroes in on cancer cells and destroys them from the inside out. Designed to exploit cancer’s unique chemistry—its acidity...
Page 1 of 21212345...102030...»Last »

Recent Posts

  • New Bio-Implant for Spinal Cord Repair
  • Seattle jury awards $24M in lawsuit against stem cell center
  • Phase I/II study finds intravitreal CD34+ stem cells safe and feasible in CRVO
  • After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
  • More Sensitive Cell Therapy May Be a HIT Against Solid Cancers
  • New iron nanomaterial wipes out cancer cells without harming healthy tissue
World Stem Cell Summit Logo - White version
Copyright © 2026 Regenerative Medicine Foundation, All rights reserved.
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow